Nicotine Treatment of Mild Cognitive Impairment (MCI)

Double-Blind Treatment of Mild Cognitive Impairment (MCI) With Transdermal Nicotine or Transdermal Placebo

The purpose of this 12-month study is to determine whether nicotine, administered in the form of nicotine patches, can improve symptoms of memory loss in some people experiencing mild memory problems (referred to in this study as "mild cognitive impairment" or MCI).

Study Overview

• Status: Unknown
• Conditions: Age-Related Memory Disorders
• Intervention / Treatment: Drug: Placebo transdermal patch; Drug: Transdermal nicotine patch

Detailed Description

The purpose of this study is to determine whether nicotine can improve symptoms of memory loss in some people experiencing mild memory problems (referred to in this study as "mild cognitive impairment" or MCI). The study will last approximately 12 months and will be conducted at 3 clinical sites in the United States.

Recent studies have suggested that one of the causes of memory disorders may be a reduction in a particular chemical substance in the brain. This chemical substance, acetylcholine, is thought to act on certain brain cells in a specific way that helps us to remember and use memories as well as affect our mood. In MCI (and Alzheimer's disease), the level of acetylcholine may be changed, and this may impair brain functioning. Preliminary studies have suggested that short-term administration of nicotine appears to improve memory in patients with mild memory loss and early Alzheimer's disease. Nicotine imitates many of the actions of acetylcholine. By administering nicotine over a longer period of time to patients with MCI, this study could lead to a better understanding of whether nicotine can act to improve memory loss symptoms over the longer term and whether it can help delay the progression of memory loss symptoms. The amount of nicotine in each patch used in this study is the same level found in patches that are used in people who are trying to quit smoking.

This study will include up to twelve visits.

• Study Type: Interventional
• Enrollment (Anticipated): 75
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • District of Columbia
    • Washington, District of Columbia, United States, 20057
      • Georgetown University Medical Center, Department of Neurology
  • North Carolina
    • Durham, North Carolina, United States, 27705
      • Duke University, Duke Health Center at Morreene Road
  • Vermont
    • Burlington, Vermont, United States, 05401
      • University of Vermont College of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Specific Inclusion Criteria:

• Age 55+.
• Memory complaints and memory difficulties which are verified by an informant.

• Abnormal memory function documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale - Revised (the maximum score is 25):

  1. less than or equal to 8 for 16 or more years of education,
  2. less than or equal to 4 for 8 - 15 years of education,
  3. less than or equal to 2 for 0 - 7 years of education.
• Mini-Mental Status Exam score between 24 and 30 (inclusive).
• Clinical Dementia Rating of 0.5 with a memory box score of 0.5 or 1.0.
• General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the screening visit.
• No significant cerebrovascular disease: Modified Hachinski score of less than or equal to 4.
• Stable medications for at least 1 month prior to screening.
• Hamilton Depression rating scale score of less than or equal to 12 on the 17-item scale.
• Informant is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more).
• Adequate visual and auditory acuity to allow neuropsychological testing.
• Good general health with no additional diseases expected to interfere with the study.
• Any conditions that subject may have must be stable for 3 months prior to screening.
• Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile).
• Participants will be taking no drugs with pro- or anti-cholinergic properties.

Exclusion Criteria:

• Any significant neurologic disease such as Alzheimer's disease, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
• Major depression or another major psychiatric disorder as described in DSM-IV within the past 2 years.
• History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
• Any significant, unstable medical condition.
• Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening.
• Any tobacco use within the past year.

Exceptions to these specific Inclusion and Exclusion Criteria (e.g., WMS-R cutoffs) may be made on a case by case basis by the Principal Investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo Group; Placebo for first six months of study; moved to open-label active nicotine for second six months	Drug: Placebo transdermal patch; placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
Experimental: Active Nicotine Group; Blinded active nicotine for first six months of study; open-label active nicotine for second six months	Drug: Transdermal nicotine patch; double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week; Other Names: Nicotrol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety of transdermal nicotine patch	13 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in cognitive performance	13 months
Change in global functioning	13 months

Collaborators and Investigators

• Sponsor: National Institute on Aging (NIA)
• Investigators: Principal Investigator: Paul Newhouse, MD, University of Vermont

Publications and helpful links

General Publications

• Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol. 2004 Feb;4(1):36-46. doi: 10.1016/j.coph.2003.11.001.
• Newhouse P, Singh A, Potter A. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr Top Med Chem. 2004;4(3):267-82. doi: 10.2174/1568026043451401.
• Newhouse PA, Potter A, Kelton M, Corwin J. Nicotinic treatment of Alzheimer's disease. Biol Psychiatry. 2001 Feb 1;49(3):268-78. doi: 10.1016/s0006-3223(00)01069-6. No abstract available.

Helpful Links

• Nicotine Treatment of Mild Cognitive Impairment (MCI) study at University of Vermont

Study record dates

Study Major Dates

• Study Start: September 1, 2003
• Primary Completion (Anticipated): July 1, 2008
• Study Completion (Anticipated): July 1, 2008

Study Registration Dates

• First Submitted: September 9, 2004
• First Submitted That Met QC Criteria: October 13, 2004
• First Posted (Estimate): October 14, 2004

Study Record Updates

• Last Update Posted (Estimate): January 15, 2008
• Last Update Submitted That Met QC Criteria: January 7, 2008
• Last Verified: January 1, 2008

More Information

Terms related to this study

• Keywords: Nicotine; Mild Cognitive Impairment (MCI); Age-Related Memory Loss
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Neurocognitive Disorders; Cognition Disorders; Cognitive Dysfunction; Memory Disorders; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Nicotine
• Other Study ID Numbers: IA0060; R01AG022462-02 (U.S. NIH Grant/Contract)